For example, amelioration of insulin resistance and hyperglycaemia by the PPARγ agonist pioglitazone or by metformin in patients with type 2 diabetes is accompanied by reduced plasma chemerin (Esteghamati et al., 2014), whereas treatment of mice with the PPARγ agonist rosiglitazone increased chemerin mRNA levels in adipose tissue and circulating chemerin levels (Muruganandan et al., 2011). This evidence concerns the gene RARRES2 and Hyperglycemia.